Company news

Adial Pharmaceuticals, Inc news in 2023

Adial Pharmaceuticals, Inc's news releases, calls and decks from 2023, newest first.

View company

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

December 19, 2023

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

November 28, 2023

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

October 23, 2023

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

October 19, 2023

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

October 18, 2023

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

August 22, 2023

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 20, 2023

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

August 3, 2023

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

July 10, 2023

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business

May 9, 2023

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

March 20, 2023

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

March 5, 2023

Adial Pharmaceuticals Schedules Business Update Conference Call

March 1, 2023

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

February 26, 2023

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

February 23, 2023

Adial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use Disorder

February 20, 2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

January 31, 2023

Decks in 2023